Literature DB >> 2955550

Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice.

J Mönkkönen, P Ylitalo, H A Elo, M M Airaksinen.   

Abstract

The distribution of 14C-labeled clodronate (dichloromethylene bisphosphonate), a new bisphosphonate for the treatment of osteolytic bone metastases and hypercalcemia, was studied in mice by whole-body autoradiography and by measuring the 14C activities in various tissues [14C]Clodronate was administered into the tail vein, and its distribution was followed from 5 min to 90 days after the injection. The drug disappeared promptly from the plasma and accumulated intensively in the bone and moderately in the spleen. In both tissues, relatively high radioactivities were measured as late as 90 days after the [14C]clodronate administration. Small amounts of 14C activity were also detected in the liver for 90 days. The results agree well with the previous observations that bisphosphonates deposit rapidly in the bone. Our findings indicate further that clodronate accumulates in the bone and the spleen for several months.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955550     DOI: 10.1016/0041-008x(87)90050-0

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  6 in total

Review 1.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Extracellular and intracellular action of clodronate in osteolytic bone diseases? A hypothesis.

Authors:  N van Rooijen
Journal:  Calcif Tissue Int       Date:  1993-06       Impact factor: 4.333

3.  The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration.

Authors:  J Mönkkönen; P Ylitalo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

4.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

5.  The pharmacokinetics and distribution of pamidronate for a range of doses in the mouse.

Authors:  C R Hoggarth; R Bennett; P T Daley-Yates
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 6.  Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  G L Plosker; K L Goa
Journal:  Drugs       Date:  1994-06       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.